Radiation-related lymphopenia is associated with spleen irradiation dose during radiotherapy in patients with hepatocellular carcinoma
Creators
- 1. Graduate Education Center, Shandong Academy of Medical Sciences, Jinan (China)
- 2. Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University Jinan, 440 Jiyan Road, Jinan, Shandong 250117 (China)
- 3. School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong (China)
- 4. Division of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas School of Public Health at Houston, 1200 Hermann Pressler St, Houston, TX 77030 (United States)
- 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 (United States)
- 6. Department of Radiation Physics, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong (China)
- 7. Laboratory for TCM Immunopharmacology and Molecular Biology, Institute of Basic Medicine, Shandong Academy of Medical Sciences, 18877 Jingshi Road, Jinan, 250062 (China)
- 8. Shandong University School of Medicine, Jinan, Shandong 250062 (China)
Description
The decrease in peripheral blood lymphocytes induced by radiation lessens the antitumour effect of the immune response, which might cause immunosuppression. We aimed to investigate the correlation between the decrease in peripheral blood lymphocytes during radiotherapy (RT) and the spleen irradiation dose in patients with hepatocellular carcinoma (HCC). The subjects were 59 patients with HCC who had received RT from 2005 to 2014. The Min ALC (minimum value of absolute counts for peripheral blood lymphocytes) was collected from the routine workup for each patient prior to RT and weekly during RT. Spleen dose-volume variables, including the percentage of the organ volume receiving ≥ n Gy (Vn) and the mean spleen dose (MSD), were calculated using Eclipse treatment planning. Potential associations between dosimetric variables and the Min ALC were assessed by multiple linear regression analysis. Peripheral lymphocytes decreased during RT (P < 0.001). The Min ALC correlated with the MSD (P = 0.005), spleen V5 (P = 0.001), spleen V25 (P = 0.026) and spleen V30 (P = 0.018). Controlling for the Karnofsky performance status (KPS), sex, age, Child-Pugh grade, total dose and tumour stage, a multiple linear regression model with bootstrap analysis of 1000 replicates showed that only the spleen V5 was correlated with the decrease in the Min ALC (P < 0.05). According to the receiver-operating characteristic (ROC) curve analysis, the predictive cutoff values of the MSD, V5, V25 and V30 of the spleen for the Min ALC were 227.72 cGy, 17.84, 0.98 and 0.42%, respectively (P = 0.002, P = 0.004, P = 0.007 and P = 0.002, respectively). Furthermore, an MSD ≥ 227.72 cGy (OR = 14.39; 95% CI, 12.18 to 16.60) and V5 (OR = 7.99; 95% CI, 6.91 to 9.07) of the spleen significantly predicted the Min ALC. Higher spleen irradiation doses were significantly correlated with lower Min ALC during RT for HCC. V5 should be limited in clinical practice. Maximum sparing for spleen irradiation during RT is recommended to preserve peripheral blood lymphocytes, which may decrease immunosuppression.
Availability note (English)
Available from http://dx.doi.org/10.1186/s13014-017-0824-x; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450236Additional details
Identifiers
Publishing Information
- Journal Title
- Radiation Oncology (Online)
- Journal Volume
- 12
- Journal Page Range
- vp.
- ISSN
- 1748-717X
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 49082394
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CARCINOMAS; DOSIMETRY; GY RANGE; IRRADIATION; LYMPHOCYTES; LYMPHOPENIA; PATIENTS; RADIATION DOSES; RADIOTHERAPY; SPLEEN
- Descriptors DEC
- ABSORBED DOSE RANGE; ANIMAL CELLS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY; BODY FLUIDS; CONNECTIVE TISSUE CELLS; DISEASES; DOSES; HEMIC DISEASES; IMMUNE SYSTEM DISEASES; LEUKOCYTES; LEUKOPENIA; MATERIALS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; SOMATIC CELLS; SYMPTOMS; THERAPY
Optional Information
- Copyright
- Copyright (c) The Author(s). 2017
- Notes
- PMCID: PMC5450236; PMID: 28558844; PUBLISHER-ID: 824; OAI: oai:pubmedcentral.nih.gov:5450236